New Chromane-Based Derivatives as Inhibitors of Mycobacterium tuberculosis Salicylate Synthase (MbtI): Preliminary Biological Evaluation and Molecular Modeling Studies
作者:Elena Pini、Giulio Poli、Tiziano Tuccinardi、Laurent Chiarelli、Matteo Mori、Arianna Gelain、Luca Costantino、Stefania Villa、Fiorella Meneghetti、Daniela Barlocco
DOI:10.3390/molecules23071506
日期:——
the need for new antitubercular drugs is desperate. The recently validated target salicylate synthase MbtI is the first enzyme involved in the biosynthesis of mycobactins, compounds able to chelate iron, an essential cofactor for the survival of Mycobacterium tuberculosis in the host. Here, we report on the synthesis and biological evaluation of chromane-based compounds as new potential inhibitors of
结核病是世界范围内单一传染源导致死亡的主要原因;因此,迫切需要新的抗结核药物。最近经过验证的目标水杨酸合酶 MbtI 是第一种参与分枝杆菌素生物合成的酶,分枝杆菌素是一种能够螯合铁的化合物,铁是结核分枝杆菌在宿主中存活的重要辅助因子。在这里,我们报告了基于色烷的化合物作为 MbtI 的新潜在抑制剂的合成和生物学评价。我们的方法成功地鉴定了一种新型先导化合物 (1),该化合物对这种酶具有良好的活性 (IC50 = 55 μM)。进行分子建模研究以评估 1 的结合模式并使初步构效关系合理化,